TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03533816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EAGD T-cell infusion (Phase I)
Description: The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EAGD T-cell infusion (Expansion)
Description: The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
Study: NCT03462927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 Cream
Description: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAL/BDP combination
Description: Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)
Study: NCT00249808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efalizumab - anti-CD11a recombinant human monoclonal antibody
Description: Participants will receive efalizumab 1.0 milligram per kilogram (mg/kg) (with an initial conditioning dose of 0.7 mg/kg) once weekly by subcutaneous injection for 12 weeks (first treatment \[FT\]). Depending on the response at Week 12, participants could receive additional 8 to 12 weekly injections of efalizumab 1.0 mg/kg.
Study: NCT01762384

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LSC
Description: subjects of this group are submitted to surgical treatment of laparoscopic sacral colpopexy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified PFRS
Description: subjects of this group are submitted to modified pelvic floor reconstructive surgery with mesh.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gynemesh
Description: Both surgeries will be conducted using mesh constructed from polypropylene mesh.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gynemesh
Description: Both surgeries will be conducted using mesh constructed from polypropylene mesh.
Study: NCT01297894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colistin
Description: Colistimethate sodium 2.5-5mg/kg of colistin base

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colistin plus fosfomycin
Description: colitimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
Study: NCT04044781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN14770, T2310
Description: Subjects will be administered radio ligand T2310 and BPN14770 to determine brain occupancy of BPN14770.
Study: NCT00989196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human-cl rhFVIII
Description: 50 IU/kg for PK dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Kogenate FS
Description: 50 IU/kg for PK dose
Study: NCT00482742

Intervention type: DEVICE
Group type: OTHER
Intervention: CiTop(TM) Guidewire
Study: NCT03058289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT230-6
Description: INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.~The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT230-6
Description: INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.~The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody
Description: The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC and DEC2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CTLA-4 antibody
Description: The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC
Study: NCT02278055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Study: NCT01565057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sedimenting meal
Description: The active system quickly forms a sedimenting layer of small particles that contain most of the caloric content of the system. This system is made by adding finely grated cheese (particle size 0.5-2 mm) to yoghurt and consumption is followed by drinking 327 ml water.
Study: NCT00443872

Intervention type: DRUG
Group type: OTHER
Intervention: orally disintegrating selegiline (Zelapar)
Description: 1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated
Study: NCT04182477

Intervention type: DIAGNOSTIC_TEST
Intervention: Montreal Cognitive Assessment
Description: Neuro-cognitive test evaluating general mental status and performance

Intervention type: DIAGNOSTIC_TEST
Intervention: Montreal Cognitive Assessment
Description: Neuro-cognitive test evaluating general mental status and performance
Study: NCT03861104

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical educational video
Description: information based on visual and auditory communication
Study: NCT03302026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Realtime biofeedback using fMRI
Description: Real-time fMRI (rt-fMRI) allows for rapid analysis of brain activation while an individual is actively performing a task, and can be used to provide real-time neurofeedback to individuals during fMRI scanning. Using neurofeedback, individuals can learn to modulate activity in specific regions of the brain. We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. Participants will complete four sessions: an intake session and 3 scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm.
Study: NCT01696058

Intervention type: DRUG
Group type: OTHER
Intervention: Tiotropium
Description: marketed product

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo matching Olodaterol
Description: one dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: marketed product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: one dose
Study: NCT03510962

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: no intervention
Description: Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test mixed fruit juice without any intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2: tap water gargle
Description: The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 3: 0.2% Chlorhexidine
Description: The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 4: Fluoridated tooth paste
Description: The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 5: Polyol containing gum
Description: The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 6: 1% sodium bicarbonate solution
Description: The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
Study: NCT04624919

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hot/Dry
Description: Work is completed in a hot/dry environment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm/Humid
Description: Work is completed in a warm/humid environment
Study: NCT04251234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light intensity, ~30 lux
Description: \~30 lux compared to very dim light baseline condition \<1 lux

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light intensity, ~30 lux
Description: \~30 lux compared to very dim light baseline condition \<1 lux

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline light intensity, <1 lux
Description: Very dim light condition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline light intensity, <1 lux
Description: Very dim light condition
Study: NCT02266121

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: Device: transcranial direct current stimulation tDCS tdcs (ELDITH, Neuroconn, Ilmenau, Germany)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Device: transcranial direct current stimulation tDCS tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
Study: NCT00187486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: Tarceva (erlotinib hydrochloride; previously referred to as OSI-774), a quinazoline, is an orally active, potent, selective inhibitor of EGFR tyrosine kinase. 100 - 300 milligrams (mg) every day (QD) orally (PO) every (q) 28 days depending on EIAED Status

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodar
Description: Temodar 200 mg/m\^2/day x 5 days every 28 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiotherapy will be administered in 180 centigray(cGy)/day - 200cGy/day fractions delivered 5 days per week to a total dose of 5940cGy - 6100cGy. A total of 4500cGy will be delivered to the clinical tumor volume consisting of T2-bright edema + a 2centimeter margin, or, if no edema, the contrast enhancing lesion +2.5 centimeter margin. An additional boost of 1440cGy will be delivered to the gross tumor volume consisting of the contrast enhancing lesion + a 1 centimeter margin.
Study: NCT01184794

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levobupivacaine
Description: 40 ml over 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Description: 40 ml over 48 hours
Study: NCT00121602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin Alfa
Description: Initial dose, frequency and route of administration of study drug will be the same as that administered for darbepoetin alfa prior to enrollment. Frequency either once a week or once every two weeks, frequency may not change for duration of study. Route of administration either subcutaneous or intravenous, route of administration may not change for duration of study. Study drug provided in pre-filled syringes at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100 or 150 ug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Initial dose, frequency and route of administration of study drug will be the same as that administered for darbepoetin alfa prior to enrollment. Frequency either once a week or once every two weeks, frequency may not change for duration of study. Route of administration either subcutaneous or intravenous, route of administration may not change for duration of study. Study drug provided in pre-filled syringes at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100 or 150 ug.
Study: NCT00928603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal Cryoablation
Description: Cryotherapy is administered via the perineum under ultrasound guidance by third-generation 17-gauge cryoprobes using gas and thermal couples. Under transrectal ultrasound guidance cryoprobes are placed approximately 1 cm apart and within 5 mm of the capsule on the side of tumor. The extent of freezing was limited to the area or lobe of the gland with histologically proved tumor.
Study: NCT00759031

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Monofluorophosphate
Description: Brush teeth and evaluate plaque score after one use of the study toothpaste
Study: NCT03407027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadratus triamcinolone
Description: 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
Study: NCT01216787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Study: NCT00759031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/Fluoride/Copolymer
Description: Brush teeth and evaluate plaque score after one use of the study toothpaste
Study: NCT02662296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Given PO
Study: NCT01216787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01649960

Intervention type: DRUG
Group type: OTHER
Intervention: Rapamycin
Description: Oral tablets were given in the dose of 0.5mg, 1mg, or 2mg once a day. This was a pilot study and the serum rapamycin levels were kept below 6ng/ml.
Study: NCT01283035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01806766

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ceramic on Ceramic bearing
Description: cementless Total Hip Arthroplasty with Ceramic on ceramic bearing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ceramic on Highly crosslinked polyethylene bearing
Description: Cementless Total Hip Arthroplasty with Ceramic on Highly crosslinked polyethylene bearing
Study: NCT05404295

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Umbilical cord blood platelel lysate gel
Description: For the treatment group, a gel from Umbilical cord blood platelel lysat will be applied in the ulcer, and then a few layers of sterile gauze, and non-compressible bandage will be used to cover the wound/ulcer area.
Study: NCT03407027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gluteus triamcinolone
Description: 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
Study: NCT04856501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PALS intervention condition
Description: The Play and Learning Strategies (PALS) intervention provides parents with behaviors that, collectively, are known as a responsive parenting style. Four constructs make up this responsive parenting style: 1) contingent responsiveness, (responses are conditionally linked to the child's signals) 2) warm sensitivity (high levels of affection and understanding of child states), 3) maintaining vs. redirecting attention, and 4) verbal scaffolding (providing child appropriate language supports). Parents assigned to this intervention will be paired with a coach who will guide them through the program over the course of 9 weekly sessions. The intervention (ePALS) will be implemented via an internet adaptation through the Children's Learning Institute's ENGAGE platform. However, ePALS could easily be adapted for other platforms and accessed with any web-enabled device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: Families assigned to the control condition will be provided with a website with information corresponding to milestones of toddler development. Control families will be asked to review that week's materials before the each of the 9 weekly coach calls. The active control condition serves three important purposes: 1) Maintains an active line of communication and accurate contact records for Post-test 1 and Post-test 2 session scheduling; 2) Masks participant's awareness of intervention vs. control assignment; and 3) Approximates communication with intervention staff such that results showing ePALS effects are attributable to intervention rather than regular communication with an interventionist.
Study: NCT02113553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Triptorelin administered once every 28 days in addition to chemotherapy
Study: NCT03407027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quadratus without triamcinolone.
Description: 10ml of levobupivacaine 0,25%.
Study: NCT05404295

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical cord blood platelel lysate gel
Description: For the treatment group, a gel from Umbilical cord blood platelel lysat will be applied in the ulcer, and then a few layers of sterile gauze, and non-compressible bandage will be used to cover the wound/ulcer area.
Study: NCT01129609

Intervention type: DEVICE
Intervention: Talent Converter Stent Graft and Talent Occluder with Occluder Delivery System
Description: All subject enrolled will be attempted to be treated with or will be treated with the Talent Converter Stent Graft
Study: NCT02885753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin intravenous
Description: 85 mg/m² in intravenous. 1 cycle each 15 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin intravenous
Description: 85 mg/m² in intravenous. 1 cycle each 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 FU bolus
Description: 5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous) following by 2400 mg/m² during 46 hours in intravenous
Study: NCT02885753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 FU bolus
Description: 5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous) following by 2400 mg/m² during 46 hours in intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: 400 mg/m² in intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: 400 mg/m² in intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic acid
Description: 400 mg/m² in intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic acid
Description: 400 mg/m² in intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin intra-arteriel
Description: 85 mg/m² in intra-arterial. 1 cycle each 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin intra-arteriel
Description: 85 mg/m² in intra-arterial. 1 cycle each 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Only for patient RAS wild: 6 mg/Kg at each cycle in intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Only for patient RAS wild: 6 mg/Kg at each cycle in intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg at each cycle in intravenous
Study: NCT03333109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: 70 mg/mL pre-filled syringe administered subcutaneously
Study: NCT03369340

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P3P 1
Description: 2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Study: NCT01243112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Lidocaine with Epinephrine (1:100,000)
Description: 0.2ml Intradermal injection once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Bupivacaine with Epinephrine (1:200,000)
Description: 0.2ml Intradermal injection once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Lidocaine, 0.125 Bupivacaine, and epi (1:150,000)
Description: 0.2ml Intradermal injection once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000)
Description: 0.2ml Intradermal injection once.
Study: NCT04990700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial rib resection
Description: 1 cm partial rib resection during thoracotomy opening
Study: NCT03594058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solabegron modified release tablets, low dose
Description: Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
Study: NCT02885753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg at each cycle in intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg at each cycle in intravenous
Study: NCT03594058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solabegron modified release tablets, high dose
Description: Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
Study: NCT03333109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: 70 mg/mL pre-filled syringe administered subcutaneously

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo in pre-filled syringe administered subcutaneously
Study: NCT02885753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg at each cycle in intravenous
Study: NCT01447706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: MM-121 (SAR256212) (IV)
Study: NCT02885753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 FU continuous
Description: 2400 mg/m² intravenously over 46 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 FU continuous
Description: 2400 mg/m² intravenously over 46 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 FU continuous
Description: 2400 mg/m² intravenously over 46 hours
Study: NCT01129765

Intervention type: DEVICE
Intervention: Use of an automatic nasal irrigator/aspirator
Description: After reading the device's user manual, parents were asked to use it on their congested children to their satisfaction. During this time, a clinical observer recorded predetermined steps that needed to be performed for success as well as presence of any adverse events.
Study: NCT01202188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol and glycopyrronium (QVA149)
Description: Capsules for inhalation delivered via SDDPI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glycopyrronium (NVA237)
Description: Capsules for inhalation delivered via SDDPI.